Amendments to the Claims

Listing of Claims:

1 - 9 (canceled)

10. (currently amended) A method of treating or ameliorating neuropathic pain, comprising administering to a patient in need thereof a first agent which is a ~~sodium channel blocker~~ semicarbazone represented by Formula I



I

where R_1-R_4 are independently hydrogen, halogen, C_{1-9} alkyl, C_{3-9} cycloalkyl, cyano, C_{1-9} alkoxy, or C_{6-10} aryloxy; R_5 is hydrogen, C_{1-9} alkyl, C_{3-9} cycloalkyl, or C_{6-10} aryl; and X is oxygen or sulfur; and

a second agent selected from the group consisting of gabapentin, pregabalin, salts thereof and combinations thereof;

wherein ~~the total amount of~~ said first agent and said second agent ~~is~~ are present in synergistic amounts effective to treat or ameliorate neuropathic pain.

11. (previously presented) The method of claim 10, wherein said method is treating neuropathic pain.

12. (previously presented) The method of claim 10, wherein said neuropathic pain is due to cancer pain or idiopathic pain.

13. (previously presented) The method of claim 10, wherein said neuropathic pain is due to trigeminal neuralgia, acute herpetic neuralgia, acute postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, or phantom limb pain.

14. (previously presented) The method of claim 13, wherein said neuropathic pain is due to trigeminal neuralgia.

15. (previously presented) The method of claim 13, wherein said neuropathic pain is due to diabetic neuropathy.

16. (canceled)

17. (original) The method of claim 10, wherein said first agent and said second agent are administered substantially simultaneously.

18. (original) The method of claim 10, wherein said first agent and said second agent are administered separately.

19. (original) The method of claim 10, wherein said first agent and said second agent are administered as part of a single pharmaceutical preparation.

20. (original) The method of claim 10, wherein said first agent and said second agent are administered intramuscularly, wherein the dose of said second agent is about 25 mg/day to about 1600 mg/day.

21. (original) The method of claim 11, wherein said first agent is administered orally.

22 - 33 (canceled)

34. (original) The method of claim 21, wherein said first agent is 4-(4'-fluorophenoxy)-benzaldehyde semicarbazone.

35. (original) The method of claim 34, wherein the amount of 4-(4'-fluorophenoxy)benzaldehyde semicarbazone is from about 50 to about 1200 mg/day.

36. (original) The method of claim 35, wherein the amount of 4-(4'-fluorophenoxy)benzaldehyde semicarbazone is from about 200 to about 900 mg/day.

37. (original) The method of claim 36, wherein the amount of 4-(4'-fluorophenoxy)benzaldehyde semicarbazone is from about 200 to about 750 mg/day.

38. (original) The method of claim 37, wherein the amount of 4-(4'-fluorophenoxy)benzaldehyde semicarbazone is from about 200 to about 600 mg/day.

39. (original) The method of claim 36, wherein the amount of 4-(4'-fluorophenoxy)benzaldehyde semicarbazone is from about 350 to about 900 mg/day.

40. (original) The method of claim 11, wherein said second agent is administered orally.

41. (original) The method of claim 40, wherein said second agent is gabapentin.

42. (original) The method of claim 41, wherein the amount of gabapentin is from about 100 to about 3200 mg/day.

43. (original) The method of claim 42, wherein the amount of gabapentin is from about 100 to about 1800 mg/day.

44. (original) The method of claim 43, wherein the amount of gabapentin is from about 150 to about 900 mg/day.

45. (original) The method of claim 43, wherein the amount of gabapentin is from about 300 to about 1800 mg/day.

46. (original) The method of claim 40, wherein said second agent is pregabalin.

47. (original) The method of claim 46, wherein the amount of pregabalin is from about 75 to about 900 mg/day.

48. (original) The method of claim 47, wherein the amount of pregabalin is from 75 to about 450 mg/day.

49. (original) The method of claim 47, wherein the amount of pregabalin is from about 150 to about 900 mg/day.

50. (original) The method of claim 11, wherein said first agent is administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, or buccally.

51. (original) The method of claim 11, wherein said second agent is administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, or buccally.

52. (currently amended) A method of treating or ameliorating neuropathic pain, comprising administering substantially simultaneously to a patient in need thereof a ~~sodium channel blocker~~ semicarbazone represented by Formula I



I

where R_1-R_4 are independently hydrogen, halogen, C_{1-9} alkyl, C_{3-9} cycloalkyl, cyano, C_{1-9} alkoxy, or C_{6-10} aryloxy; R_5 is hydrogen, C_{1-9} alkyl, C_{3-9} cycloalkyl, or C_{6-10} aryl; and X is oxygen or sulfur; and

at least one of gabapentin and pregabalin,

wherein said ~~sodium channel blocker~~ semicarbazone and at least one of gabapentin and pregabalin are administered in synergistic amounts effective to treat or ameliorate neuropathic pain.